New Study Reveals n-3 PUFAs and FFA4 Activation as Promising Therapy for Rheumatoid Arthritis

May 28, 2024
New Study Reveals n-3 PUFAs and FFA4 Activation as Promising Therapy for Rheumatoid Arthritis
  • Researchers explored the benefits of activating Free Fatty Acid Receptor 4 (FFA4) to reduce collagen-induced rheumatoid arthritis (CIA).

  • The study, published in the International Journal of Molecular Sciences, found that n-3 polyunsaturated fatty acids (PUFA) could be effective in treating rheumatoid arthritis.

  • An FFA4 agonist named compound A (CpdA) was used in mice with and without the Ffa4 gene.

  • CpdA suppressed arthritis symptoms, immune responses, and pro-inflammatory cytokines in Ffa4 WT mice, but not in KO mice.

  • Activation of FFA4 rebalanced Th1/Th17 and Treg cells, reducing inflammation and alleviating arthritis characteristics.

  • CpdA showed positive effects on synovial cells and dendritic cell activation, decreasing inflammatory immune responses.

  • The findings suggest that FFA4 activation through n-3 PUFAs and CpdA could be a promising adjuvant therapy for rheumatoid arthritis.

Summary based on 2 sources


Get a daily email with more Science stories

More Stories